Abstracts tagged "giant cell arteritis"

Abstract Number: 2397 • ACR Convergence 2023
Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis
Milena Bond¹, Alessandro Tomelleri², Maria Antonietta Reatini³, Corrado Campochiaro⁴, Giorgio Cattani³, Lorenzo Dagna⁵, Maurizio Rossini⁶, Christian Dejaco⁷ and Giovanni Adami⁶, ¹Azienda sanitaria dell'Alto Adige, Merano, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³Italian Institute for Environmental Protection and Research, Rome, Italy, ⁴IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁵Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ⁷Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy
Background/Purpose: Environmental air pollution (AP) has been found to affect vascular inflammation and to contribute to the risk of onset and flare of autoimmune diseases1,2.…
Abstract Number: 2413 • ACR Convergence 2023
Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review
Fernando López¹, Javier Loricera², Toluwalase Tofade³, Diana Prieto-Peña², Susana Romero Yuste⁴, Eugenio De Miguel⁵, Anne Riveros-Frutos⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸, Eztizen Labrador-Sánchez⁹, Olga Maiz¹⁰, Elena Becerra-Fernández¹¹, Javier Narvaez¹², Eva Galindez-Agirregoikoa¹³, Ismael González¹⁴, Ana Urruticoechea¹⁵, Sebastian Unizony¹⁶ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Neurology Department, Massachusetts General Hospital, Boston, MA, ⁴Complexo Hospitalario Universitario, Pontevedra, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital Universitario San Pedro, Laguardia, Spain, ¹⁰Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Torrevieja, London, United Kingdom, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de León, León, Spain, ¹⁵Hospital Can Misses, Ibiza, Spain, ¹⁶Massachusetts General Hospital, Winchester, MA, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with giant cell arteritis (GCA) can relapse despite glucocorticoids, methotrexate and tocilizumab treatment. The JAK/STAT signalling pathway is involved in the pathogenesis of…
Abstract Number: 2600 • ACR Convergence 2023
Clonal Hematopoiesis Is Associated with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is an age-related vasculitis of large and medium vessels. Prior population studies have identified an association between GCA and hematologic…
Abstract Number: 0707 • ACR Convergence 2023
Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
Chiara Marvisi¹, Giulia Besutti², Pamela Mancuso³, Roberto Farì⁴, Filippo Monelli⁴, Matteo Revelli⁴, Rexhep Durmo⁵, Elena Galli⁶, Francesco Muratore⁷, Lucia Spaggiari², Marta Ottone³, Stefano Luminari⁸, Pierpaolo Pattacini⁴, Paolo Giorgi Rossi³ and Carlo Salvarani⁹, ¹IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ³Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁴Radiology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁵Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁸Ematology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Arterial wall calcifications are a hallmark of atherosclerosis and represent an important cardiovascular risk factor. Accelerated atherosclerosis and vascular calcifications have been reported in…
Abstract Number: 1877 • ACR Convergence 2023
Diagnostic Yield of 18F-FDG PET-CT for Large Vessel Involvement in Patients with Suspected Giant Cell Arteritis and Negative Temporal Artery Biopsy
Javier Narvaez¹, Paula V. Estrada-Alarcón², Paola Vidal-Montal³, Iván Sánchez-Rodriguez⁴, Aida Sabate-Llobera⁴, Montserrat Cortes-Romera⁴ and Joan Miquel Nolla⁵, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Department of Nuclear Medicine – PET IDI. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Every effort should be made to confirm a suspected diagnosis of giant cell arteritis (GCA). According to the 2018 update of the EULAR recommendations…
Abstract Number: 2398 • ACR Convergence 2023
FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study
Geoffroy Peyrac¹, Arthur Mageau², Augustin Gaudemer², Khadija Benali¹, Jean-Francois Alexandra¹, Andrey Strukov¹, Sebastien Ottaviani¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France
Background/Purpose: Steroids and anti-IL6 biotherapy are highly effective in obtaining remission in patients with giant cell arteritis (GCA) but the risk of relapses remains high,…
Abstract Number: 2414 • ACR Convergence 2023
Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors
Fernando López¹, Javier Loricera², Ivan Ferraz Amaro³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, Juan I. Villa¹⁰, PALOMA VELA¹¹, Susana Romero Yuste¹², Jose L. Callejas¹³, Eugenio De Miguel¹⁴, Eva Galindez-Agirregoikoa¹⁵, Francisca Sivera¹⁶, Jesús Carlos Fernández López¹⁷, Arturo Llobell¹⁸, Julio Sánchez-Martín¹⁹, Calderon Goercke², Lara Sanchez-Bilbao²⁰, Jose L. Hernández²¹ and Ricardo Blanco²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Torrelavega, Spain, ¹¹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹²Complexo Hospitalario Universitario, Pontevedra, Spain, ¹³Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁴Hospital Universitario La Paz, Madrid, Spain, ¹⁵Basurto University Hospital, Bilbao, Spain, ¹⁶Elda General University Hospital, Elda, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸Parc Tauli University Hospital, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ²⁰Hospital Universitario Marques de Valdecilla, Santander, Spain, ²¹Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trial with TCZ in GCA was performed with intravenous (iv)…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 0747 • ACR Convergence 2023
Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
Abstract Number: 2399 • ACR Convergence 2023
Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹, Tanaz Kermani², Lene Kristin Brekke³, Oyvind Molberg⁴ and Andreas Diamantopoulos⁵, ¹Martina Hansens Hospital, Hosle, Norway, ²Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ³Haugesund Hospoital For Rheumatic Diseases, Haugesund, Nepal, ⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: Patients with Giant cell arteritis (GCA) face an elevated risk of aneurysm formation. Despite this, consensus regarding optimal aortic visualization methods and aneurysm monitoring…
Abstract Number: 2415 • ACR Convergence 2023
Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Artem Minalyan¹, Christopher Hino¹, Emily He¹, Osahon Idolor², Chinenye Osuorji³, Nneka Chukwu⁴, Ehizogie Edigin¹ and Vaneet Sandhu⁵, ¹Loma Linda University Health, Loma Linda, CA, ²Piedmont Athens Regional Hospital, Atlanta, GA, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁴Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁵Loma Linda University, Loma Linda, CA
Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…
Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: 0766 • ACR Convergence 2023
The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Valentin Sebastian Schäfer¹, Tobias Schremmer², Florian Recker³, Wolfgang Hartung⁴, Christina Duftner⁵, Sara Monti⁶, Alojzija Hocevar⁷, Rositsa Karalilova⁸, Annamaria Iagnocco⁹, PIERLUIGI MACCHIONI¹⁰, Giuseppe Antonio Germano¹¹, Maria Esperanza Naredo Sanchez¹², Eugenio De Miguel¹³, Luca Seitz¹⁴, Thomas Daikeler¹⁵, Markus Aschwanden¹⁶, Dennis Boumans¹⁷, Chetan Mukhtyar¹⁸, smith kate¹⁹, Richard Wakefield²⁰, Andreas Diamantopoulos²¹, Stavros Chrysidis²², Berit Dalsgaard Nielsen²³, Kresten Keller²⁴, Uffe Dohn²⁵, Lene Terslev²⁶, Marcin Milchert²⁷, Aaron Juche²⁸, Wolfgang Schmidt²⁹, George A. W. Bruyn³⁰ and Christian Dejaco³¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Universitätsklinikum Bonn, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Bonn, Germany, ⁴Asklepios Clinic, Tegernheim, Germany, ⁵Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁶Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁷Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ⁹University of Turin, Roma, Italy, ¹⁰Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹¹Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, ¹²Rheumatology Department and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ¹⁵Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ¹⁶Department of Angiology, University Hospital Basel, Basel, Switzerland, ¹⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ¹⁸Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²⁰s Leeds Insitute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²¹Akershus University Hospital, Lørenskog, Norway, ²²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ²³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ²⁴Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²⁵Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, ²⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²⁷Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²⁹Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³⁰Reumakliniek Lelystad, Loenga, Netherlands, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). There is a need to develop training resources, because the glucocorticoid…
Abstract Number: 1882 • ACR Convergence 2023
Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations
Philipp Bosch¹, Milena Bond², Christian Dejaco³, Cristina Ponte⁴, Sarah Mackie⁵, Louise Falzon⁶, Wolfgang Schmidt⁷ and Sofia Ramiro⁸, ¹Medical University of Graz, Graz, Austria, ²Azienda sanitaria dell'Alto Adige, Merano, Italy, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Sheffield, Sheffield, United Kingdom, ⁷Immanuel Krankenhaus Berlin, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…

« Previous Page
1
…
6
7
8
9
10
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.